1-octadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycerol : A 1,2-diacyl-sn-glycerol that has stearoyl and oleoyl as the 1- and 2-acyl groups respectively.
ID Source | ID |
---|---|
PubMed CID | 6443547 |
CHEBI ID | 75468 |
SCHEMBL ID | 7917740 |
MeSH ID | M0223812 |
Synonym |
---|
1-octadecanoyl-2-(9z-octadecenoyl)-sn-glycerol |
LMGL02010043 , |
dg(18:0/18:1(9z)/0:0)[iso2] |
dg(18:0_18:1) |
dg(18:0/18:1/0:0)[iso2] |
[(2s)-3-hydroxy-2-[(z)-octadec-9-enoyl]oxypropyl] octadecanoate |
1-stearoyl-2-oleoyl-sn-glycerol |
sn-sodg |
9-octadecenoic acid (z)-, 1-(hydroxymethyl)-2-((1-oxooctadecyl)oxy)ethyl ester, (s)- |
53702-48-0 |
1-octadecanoyl-2-[(9z)-octadecenoyl]-sn-glycerol |
(2s)-1-hydroxy-3-(octadecanoyloxy)propan-2-yl (9z)-octadec-9-enoate |
CHEBI:75468 |
SCHEMBL7917740 |
dg(18:0/18:1(9z)/0:0) |
dag(18:0/18:1n9) |
diacylglycerol(18:0/18:1n9) |
dg(18:0/18:1n9) |
dg(18:0/18:1w9) |
diacylglycerol(18:0/18:1w9) |
dag(18:0/18:1w9) |
1-steraoyl-2-oleoyl-sn-glycerol |
Q27105044 |
DTXSID301150231 |
(1s)-1-(hydroxymethyl)-2-[(1-oxooctadecyl)oxy]ethyl (9z)-9-octadecenoate |
Role | Description |
---|---|
mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
1,2-diacyl-sn-glycerol | |
1-stearoyl-2-oleoylglycerol | A 1,2-diglyceride with stearoyl and oleoyl as the acyl groups. |
diacylglycerol 36:1 | A diglyceride in which the two acyl groups contain a total of 36 carbons and 1 double bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |